AP2015008733A0 - Compositions and methods for live, attenuated alphavirus formulations - Google Patents

Compositions and methods for live, attenuated alphavirus formulations

Info

Publication number
AP2015008733A0
AP2015008733A0 AP2015008733A AP2015008733A AP2015008733A0 AP 2015008733 A0 AP2015008733 A0 AP 2015008733A0 AP 2015008733 A AP2015008733 A AP 2015008733A AP 2015008733 A AP2015008733 A AP 2015008733A AP 2015008733 A0 AP2015008733 A0 AP 2015008733A0
Authority
AP
ARIPO
Prior art keywords
live
compositions
methods
attenuated alphavirus
formulations
Prior art date
Application number
AP2015008733A
Other languages
English (en)
Inventor
Laszlo Varga
Jill A Livengood
Dan T Stinchcomb
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008733(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of AP2015008733A0 publication Critical patent/AP2015008733A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AP2015008733A 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations AP2015008733A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14
PCT/US2014/026570 WO2014151855A1 (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Publications (1)

Publication Number Publication Date
AP2015008733A0 true AP2015008733A0 (en) 2015-09-30

Family

ID=50489420

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008733A AP2015008733A0 (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Country Status (20)

Country Link
US (2) US10137186B2 (xx)
EP (2) EP3603667A1 (xx)
JP (3) JP6426695B2 (xx)
KR (1) KR20160003662A (xx)
CN (2) CN105377293B (xx)
AP (1) AP2015008733A0 (xx)
AU (2) AU2014236804B2 (xx)
BR (1) BR112015023205A2 (xx)
CA (1) CA2903711A1 (xx)
CR (1) CR20150553A (xx)
DO (1) DOP2015000226A (xx)
EC (1) ECSP20007842A (xx)
HK (1) HK1220358A1 (xx)
MX (2) MX361342B (xx)
MY (1) MY178476A (xx)
NZ (1) NZ631012A (xx)
PH (1) PH12015502115B1 (xx)
SG (3) SG10201801459SA (xx)
TW (2) TWI649087B (xx)
WO (1) WO2014151855A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151855A1 (en) 2013-03-14 2014-09-25 Inviragen, Inc. Compositions and methods for live, attenuated alphavirus formulations
US10538785B2 (en) 2013-12-23 2020-01-21 Renaud Vaillant Lyophilized lentiviral vector particles, compositions and methods
MX2018011837A (es) * 2016-03-31 2019-02-13 Takeda Vaccines Inc Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas.
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
KR20230014737A (ko) * 2021-01-19 2023-01-30 니타 젤라틴 가부시키가이샤 바이러스 안정화제, 바이러스 안정화제용 젤라틴 가수분해물 및 바이러스 함유 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6465634B1 (en) * 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
JP2002523053A (ja) * 1998-07-30 2002-07-30 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 標的化されたアルファウイルスおよびアルファウイルスベクター
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
JP2005517394A (ja) * 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
EP2591771A1 (en) 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
EP1701738B1 (en) 2003-12-17 2015-03-11 Wyeth LLC Method for producing storage stable RSV compositions
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
EP2535058A3 (en) 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
CA2720570C (en) 2007-04-06 2022-10-04 Inviragen, Inc. Methods and compositions for live, attenuated dengue viruses
EP2197487B1 (en) 2007-09-04 2016-01-06 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Thermal inactivation of rotavirus
ES2657485T3 (es) 2007-09-14 2018-03-05 Sanofi Pasteur Biologics, Llc Composiciones farmacéuticas que contienen toxoides A y B de Clostridium difficile
CN102083986B (zh) 2008-01-24 2014-06-18 德克萨斯大学系统董事会 不能在蚊子中复制的减毒重组甲病毒及其用途
SI2759306T1 (sl) * 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Imunostimulacijski oligonukleotidi
WO2011090712A2 (en) * 2009-12-28 2011-07-28 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
EP2575873B1 (en) 2010-06-01 2015-12-30 Novartis AG Concentration and lyophilization of influenza vaccine antigens
WO2014151855A1 (en) * 2013-03-14 2014-09-25 Inviragen, Inc. Compositions and methods for live, attenuated alphavirus formulations

Also Published As

Publication number Publication date
US20190134182A1 (en) 2019-05-09
US20140271715A1 (en) 2014-09-18
MX361342B (es) 2018-12-04
ECSP20007842A (es) 2020-09-30
JP2020193231A (ja) 2020-12-03
PH12015502115A1 (en) 2016-01-25
SG10201801459SA (en) 2018-03-28
TW201513875A (zh) 2015-04-16
TW201900192A (zh) 2019-01-01
CN105377293A (zh) 2016-03-02
SG10201909051QA (en) 2019-11-28
AU2014236804A1 (en) 2015-10-01
BR112015023205A2 (pt) 2017-07-18
CR20150553A (es) 2015-12-01
CA2903711A1 (en) 2014-09-25
AU2018236897B2 (en) 2020-09-10
AU2014236804B2 (en) 2018-12-13
JP2019031543A (ja) 2019-02-28
MX2018014977A (es) 2022-06-27
MY178476A (en) 2020-10-14
TWI649087B (zh) 2019-02-01
US10137186B2 (en) 2018-11-27
SG11201507462QA (en) 2015-10-29
US10806781B2 (en) 2020-10-20
PH12015502115B1 (en) 2016-01-25
JP6426695B2 (ja) 2018-11-21
JP2016513658A (ja) 2016-05-16
CN105377293B (zh) 2020-07-17
EP2968515A1 (en) 2016-01-20
MX2015012894A (es) 2016-04-04
DOP2015000226A (es) 2016-02-29
JP6761015B2 (ja) 2020-09-23
AU2018236897A1 (en) 2018-10-18
WO2014151855A1 (en) 2014-09-25
KR20160003662A (ko) 2016-01-11
EP3603667A1 (en) 2020-02-05
CN111729077A (zh) 2020-10-02
NZ631012A (en) 2017-08-25
EP2968515B1 (en) 2019-05-08
HK1220358A1 (zh) 2017-05-05

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
HK1218837A1 (zh) 組合物和方法
HK1218560A1 (zh) 組成與方法
GB2527241B (en) Compositions and methods
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
GB201319791D0 (en) Formulations
ZA201505390B (en) Compositions and methods for treating pests
GB201308072D0 (en) Compositions and methods
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
SG11201506605XA (en) Ion implantation compositions, systems, and methods
GB201319792D0 (en) Formulations
HK1213800A1 (zh) 類毒素、組合物及相關方法
EP2981529A4 (en) ORIDONIN ANALOGUES, COMPOSITIONS AND RELATED METHODS
IL266767A (en) Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter
EP2953455A4 (en) ANTIMICROBIAL COMPOSITIONS, WIPES AND METHODS
GB201305813D0 (en) Compositions and methods
IL242795B (en) Preparations, methods and devices for dialysis
IL243778A0 (en) Combined immune complexes
HK1214951A1 (zh) 眼用製劑
HK1220358A1 (zh) 減毒活甲病毒製劑的組合物和方法
HUE037525T2 (hu) Kis sejtmagvacska RNS (SNORNA), készítmények és alkalmazások
HK1213917A1 (zh) 類霉素、組合物及相關方法
HK1212916A1 (zh) 包含炮製提取物的組合物
EP3102557A4 (en) Improved compositions and methods comprising resveratrol
GB201313990D0 (en) Combination immunogenic compositions